Impact of Topiramate Migraine Prophylaxis on Workplace Productivity: Results from Two US Randomized, Double-Blind, Placebo-Controlled, Multicenter Trials

Lofland, Jennifer H.; Gagne, Joshua J.; Pizzi, Laura T.; Rupnow, Marcia F.T.; Silberstein, Stephen D.

doi:10.1097/jom.0b013e3180322134

Cited by 13 publications

(8 citation statements)

References 46 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies evaluated the impact of migraine prophylaxis on worker productivity. Lofland et al 24 found that the total rate of lost productivity per migraineur was 3.1 hours per month in the topiramate prophylaxis plus episodic treatment group compared with 4.0 hours for placebo plus episodic treatment (P=.002). Schrader et al 28 found no statistically significant difference in days of work lost between prophylaxis with lisinopril and placebo (2.30 days per 12 weeks vs 2.09 days per 12 weeks) in a crossover study that enrolled 60 patients.…”

Section: Effect Of Migraine Prophylaxis On Us Worker Productivitymentioning

confidence: 99%

“…The recall periods used in the studies identified in this review ranged from hourly assessments of productivity 31 to an annual recall period. 18,24 For studies designed to compare migraine treatments, identifying the most appropriate recall period presents a challenge. The validation study for the MWPLQ was conducted using a 24-hour recall period for a single episode.…”

Section: Recommendations For Researchersmentioning

confidence: 99%

See 1 more Smart Citation

The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future Research

Burton

Landy

Downs

et al. 2009

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Evidence suggests that migraine is associated with decreased productivity. This article describes the results of a systematic literature review of peer-reviewed publications that measured the impact of migraine on workplace productivity in the United States and provides recommendations for future research. A MEDLINE search was conducted from January 1, 1990 to July 31, 2008. Articles were included if the results were from a prospective or retrospective study that reported work-specific productivity outcomes in adults with migraine in the United States. Twenty-six studies were included. Nine studies found that diagnosed and/or undiagnosed migraine had a negative impact on worker productivity. Although one migraine prophylactic study found a statistically significant improvement in worker productivity for topiramate-treated patients, another found an insignificant difference in lisinopril-treated patients. Fifteen studies compared the impact of triptan therapy with a control group. The control groups in these studies differed with regard to recall periods, time to follow-up, and types of questionnaires used. Almost all studies found that triptan therapy was associated with a statistically significant improvement in loss in worker productivity vs the control group. Health care professionals can reduce the impact of migraine on worker productivity with appropriate therapy. Researchers should collect presenteeism and absenteeism data, report results in units of time, use a validated instrument, carefully consider recall periods, and report worker productivity separately. In addition, patients with undiagnosed migraine should be included in disease burden studies. When evaluating effects of treatment on productivity, researchers should target well-controlled, double-blind studies and conduct productivity research for new treatments.

show abstract

Section: Effect Of Migraine Prophylaxis On Us Worker Productivitymentioning

confidence: 99%

Section: Recommendations For Researchersmentioning

confidence: 99%

The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future Research

Burton

Landy

Downs

et al. 2009

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…Lofland et al 24 found that the total rate of lost productivity per migraineur was 3.1 hours per month in the topiramate prophylaxis plus episodic treatment group compared with 4.0 hours for placebo plus episodic treatment (P=.002). Schrader et al 28 found no statistically significant difference in days of work lost between prophylaxis with lisinopril and placebo (2.30 days per 12 weeks vs 2.09 days per 12 weeks) in a crossover study that enrolled 60 patients.…”

Section: Effect Of Migraine Prophylaxis On Us Worker Productivitymentioning

confidence: 99%

Section: Recommendations For Researchersmentioning

confidence: 99%

The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future Research

Burton

Landy

Downs

et al. 2009

Mayo Clinic Proceedings

View full text Add to dashboard Cite

“…Preventive therapy with topiramate was shown to be associated with significant decreases in resource use based on pharmacy data claim analyses [9] as well as an increased work place productivity based on results of randomized controlled trials [38]. …”

Section: Discussionmentioning

confidence: 99%

Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting

Nelles¹,

Schmitt²,

Humbert

et al. 2009

J Headache Pain

View full text Add to dashboard Cite

The majority of patients with migraine headaches are treated in non-specialized institutions though data on treatment outcomes are largely derived from tertiary care centers. The current non-interventional study explores efficacy and tolerability outcomes of patients with episodic migraines receiving topiramate as preventive agent in a general practice setting. A total of 366 patients (87% female, mean age 41.8 ± 11.6 years) were eligible for migraine prevention and treated with flexible dose topiramate for 6 months (core phase), and optionally for a total of 12 months (follow-up phase). Overall, 261 patients (77.7% of safety analysis set, SAF) completed the core phase. Reasons for discontinuation included adverse events (2.1%), lost to follow-up (1.8%), other reasons (1.5%), and end of therapy (0.3%) though in the majority of patients who discontinued no reasons were listed. The median daily dose at endpoint was 50 mg/day (range, 25–187.5 mg/day). The median days with migraine headaches decreased from 6.0 to 1.2 days (p < 0.001), median pain intensity score decreased from 17.0 to 3.2 points (p < 0.001). In women with reported menstruation-associated migraine, the median number of migraine attacks decreased from 4.0 to 0.9 (p < 0.001). Absenteeism as well as triptan use decreased significantly, and significant improvements in activities of daily living and quality of life were reported. The most frequently reported AEs were paraesthesia (4.2%) and nausea (3%). Results suggest that migraine prevention with topiramate in a general practice is generally well tolerated and associated with a significant improvement in migraine headaches and related functional impairment.

show abstract

Impact of Topiramate Migraine Prophylaxis on Workplace Productivity: Results from Two US Randomized, Double-Blind, Placebo-Controlled, Multicenter Trials

Abstract: Findings suggest that topiramate, compared with placebo, is associated with decreased workplace presenteeism and TLP.

Cited by 13 publications

References 46 publications

The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future Research

The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future Research

The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future Research

Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting

Contact Info

Product

Resources

About